IntelliPharmaCeutics (IPCI) Earning Somewhat Favorable News Coverage, Study Shows

News headlines about IntelliPharmaCeutics (NASDAQ:IPCI) (TSE:I) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IntelliPharmaCeutics earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.5632264631989 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have effected Accern’s analysis:

A number of brokerages recently issued reports on IPCI. Zacks Investment Research lowered shares of IntelliPharmaCeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 8th. Maxim Group reiterated a “hold” rating on shares of IntelliPharmaCeutics in a research report on Wednesday, April 18th. Finally, HC Wainwright set a $3.00 target price on shares of IntelliPharmaCeutics and gave the company a “buy” rating in a research report on Monday, March 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $2.15.

IntelliPharmaCeutics remained flat at $$0.42 on Friday, according to Marketbeat. 346,732 shares of the company were exchanged, compared to its average volume of 321,091. The company has a market cap of $18.55 million, a price-to-earnings ratio of -1.46 and a beta of 1.31. IntelliPharmaCeutics has a 12-month low of $0.32 and a 12-month high of $2.92.

IntelliPharmaCeutics (NASDAQ:IPCI) (TSE:I) last announced its earnings results on Friday, February 16th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.01). The company had revenue of $1.08 million during the quarter, compared to the consensus estimate of $1.32 million. IntelliPharmaCeutics had a negative net margin of 217.52% and a negative return on equity of 2,811.75%. equities analysts forecast that IntelliPharmaCeutics will post -0.1 EPS for the current year.

IntelliPharmaCeutics Company Profile

IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.

Insider Buying and Selling by Quarter for IntelliPharmaCeutics (NASDAQ:IPCI)

Receive News & Ratings for IntelliPharmaCeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics and related companies with's FREE daily email newsletter.

Leave a Reply